Compare FVRR & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FVRR | CMPX |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 372.4M | 408.8M |
| IPO Year | 2019 | 2020 |
| Metric | FVRR | CMPX |
|---|---|---|
| Price | $11.03 | $2.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $18.43 | $14.57 |
| AVG Volume (30 Days) | 706.2K | ★ 3.2M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.83 | $934.41 |
| P/E Ratio | $22.05 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.58 | $1.61 |
| 52 Week High | $28.00 | $6.88 |
| Indicator | FVRR | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 51.55 | 43.19 |
| Support Level | $9.93 | $1.88 |
| Resistance Level | $11.43 | $2.14 |
| Average True Range (ATR) | 0.46 | 0.11 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 40.65 | 21.43 |
Fiverr International Ltd operates a online marketplace that enables sellers to offer digital services and buyers to purchase them The Company's platform features an extensive catalog of digital services that spans over hundreds of categories. Buyers can purchase digital services ranging from simple services such as logo design and blog post writing, to complex services such as video creation, website development and social media marketing. Also, the Company offers value-added services including subscription products, advertising solutions and financial tools designed to support marketplace users and enhance their business activities. The company generates maximum of its revenue from USA.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.